Zentraxa is an exciting new spin-out from the University of Bristol. We are commercialising a disruptive design, production and testing platform for novel peptides, and are targeting several peptide candidates in the multi-billion-dollar biotherapeutic market.
We have unique access to the world-class infrastructure at Bristol's Centre for Synthetic Biology (BrisSynBio), including dedicated supercomputer capacity, an advanced robotics platform and world-leading high-throughput analytical platforms.
We have proprietary technology protected by patents and extensive technical knowhow, and a dedicated and experienced management team. We have developed a scalable business model around our peptide platform with rapid & significant growth potential.